AstraZeneca PLCAZN announced positive results from a safety study on Symbicort inhaler in patients suffering from asthma compared to budesonide alone. Symbicort is presently marketed for the treatment ...
Symbicort is a combination inhaler used to control asthma and to maintain airflow in people with chronic obstructive pulmonary disease (COPD). It contains an inhaled corticosteroid called budesonide ...
Symbicort and Advair are similar brand-name prescription medications that treat asthma and COPD. They contain slightly different active ingredients. Symbicort and Advair are two drugs that treat ...
AstraZenecaAZN announced that the FDA has granted six months of pediatric exclusivity to its Symbicort inhalation aerosol. Symbicort is a combination formulation containing budesonide, an inhaled ...
MISSISSAUGA, ON, Sept. 30, 2019 /CNW/ - AstraZeneca Canada announced today that Health Canada has approved the expanded use of Symbicort ® Turbuhaler ® (budesonide ...
Wilmington, DE – June 4, 2008 – AstraZeneca (NYSE: AZN) today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback